| 000 | 01318 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513090738.0 | ||
| 264 | 0 | _c19960701 | |
| 008 | 199607s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLegha, S S | |
| 245 | 0 | 0 |
_aEvaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. _h[electronic resource] |
| 260 |
_bCancer _cJan 1996 |
||
| 300 |
_a89-96 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aGianan, M A | |
| 700 | 1 | _aPlager, C | |
| 700 | 1 | _aEton, O E | |
| 700 | 1 | _aPapadopoulous, N E | |
| 773 | 0 |
_tCancer _gvol. 77 _gno. 1 _gp. 89-96 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4 _zAvailable from publisher's website |
| 999 |
_c8629984 _d8629984 |
||